NCCN Asia Consensus Statement prostate cancer

被引：15

作者：

Hinotsu, Shiro ^{[1
]}

Namiki, Mikio ^{[2
]}

Ozono, Seiichiro ^{[3
]}

Akaza, Hideyuki ^{[4
]}

机构：

[1] Sapporo Med Univ, Dept Biostat, Sapporo, Hokkaido, Japan

[2] Hasegawa Hosp, Dept Urol, Toyama, Japan

[3] Hamamatsu Univ Sch Med, Dept Urol, Shizuoka, Japan

[4] Univ Tokyo, Grad Sch Interdisciplinary Informat Studies, Interfac Initiat Informat Studies, Tokyo, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 48卷 / 11期

关键词：

Clinical Practice Guideline; NCCN; Asia Consensus Statement; prostate cancer; hormonal treatment;

D O I：

10.1093/jjco/hyy116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The National Comprehensive Cancer Network, an NPO organization comprised of university hospitals and cancer centers in the US. The publication of clinical practice guidelines on the treatment, diagnosis, prevention and screening is one of important activities. Background factors of prostate cancer patients, such as the prevalence, age at the diagnosis and mortality are markedly different between Western countries and Asia. Thus, various factors should be taken into consideration at the treatment choice for individual patients. Experts from Asian countries were published as the Asia Consensus Statement. In this review, we explain important points of the Asia Consensus Statement such as differences in the epidemiological backgrounds of patients, differences in treatment options and differences in medical insurance systems.

引用

页码：964 / 965

页数：2